EP4076662
Pýrasólýl-afleiður sem eru nytsamlegar sem krabbameinslyf
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.12.2020EP published:
31.1.2024EP application number:
20829365.4
EP translation filed:
15.4.2024Grant published:
15.5.2024EPO information:
European Patent Register
Max expiry date:
16.12.2040Expiry date:
16.12.2026Next due date:
31.12.2026
Title in English:
PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTSLanguage of the patent:
English
Timeline
Today
17.12.2020EP application
31.1.2024EP Publication
15.4.2024Translation submitted
15.5.2024Registration published
16.12.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
COTESTA, SimonaAddress:
4002 Basel, CH
Name:
GERSPACHER, MarcAddress:
4002 Basel, CH
Name:
LEBLANC, CatherineAddress:
4002 Basel, CH
Name:
LIU, BoAddress:
Shanghai, CN
Name:
LORTHIOIS, Edwige Liliane JeanneAddress:
4002 Basel, CH
Name:
MACHAUER, RainerAddress:
4002 Basel, CH
Name:
MAH, RobertAddress:
4002 Basel, CH
Name:
MURA, ChristopheAddress:
4002 Basel, CH
Name:
RIGOLLIER, PascalAddress:
4002 Basel, CH
Name:
SCHNEIDER, NadineAddress:
4002 Basel, CH
Name:
STUTZ, StefanAddress:
4053 Basel, CH
Name:
VAUPEL, AndreaAddress:
4002 Basel, CH
Name:
WARIN, NicolasAddress:
4002 Basel, CH
Name:
WILCKEN, RainerAddress:
4002 Basel, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962951400 PDate:
20.12.2019Country:
US
Number:
PCT/CN2020/125425Date:
30.10.2020Country:
WO
Classification
Categories:
A61P 35/00, C07D 401/14, C07D 403/04, C07D 403/14, C07D 405/14, C07D 413/14, C07D 417/14, C07D 471/04, C07D 487/04, A61K 31/416, A61K 31/4439, A61K 31/506, A61K 31/437, A61K 31/502, A61K 31/517, A61K 31/538, A61K 31/425
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 28.4.2025
Expires: 16.12.2025
Payer: Árnason Faktor ehf.
Number: 6
Paid: 19.12.2025
Expires: 16.12.2026
Payer: Árnason Faktor ehf.